新免疫抑制剂雷帕霉素抗移植排斥作用的实验研究

Inhibitory Effects of Rapamycin on the Experimental Allograft Rejection

作者研究了雷帕霉素（rapamycin;RPM）对C57BL/6J→BALB/c小鼠心肌和皮肤移植的抗移植排斥作用,结果表明 RPM比目前应用于临床器官移植的环孢菌素（Cyclosporine A;CsA）具有更好的抗移植排斥作用。此外还观察了 RPM对正在进行的移植心肌排斥反应的作用,RPM于小鼠心肌移植后第 7天开始给药与0天开始给药组相比较,移植心肌的平均存活天数无明显差异,表明RPM对心肌移植排斥反应有很好的治疗作用。小剂量的RPM与亚治疗剂量的CsA合用还有很好的协同作用。

In this study.two allogrfting models of split heart graft and skin allograft were used in two MHC-imcompatible strains of mice .Rapamycin(RPM)at a dose range of 0.5 to 2.5mg/kg/day significantly prolonged graft survival days of split heart grafts compared with those of the vehicle control. When RPM 2.0mg/kg was given i.p. for 10 days from day 7 post transplantation.it was effective to prolong graft survival to 19.0±3.0 days and the MST(mean survival time)was not statistically different from that of the treatment with RPM given from the day of transplantation. 1 mg/kg RPM also prolonged the MST of skin allograft survival from 8.7±0.52 days to 17.7±0.52 days(P<0.001).In addition,low dose RPM 0.04mg/kg and 0.08mg/kg combined with a sub-therapeutic dose of CsA lOmg/kg showed significant synergistic effect.